NCT00392769View on ClinicalTrials.gov

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Endometrial Cancer
Interventions
DRUG

Cetuximab

Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.

Trial Locations (2)

10021

New York Presbyterian Hospital-Cornell Medical Center, New York

77030

UT MD . Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER